Literature DB >> 36249460

Persistent erythematous candidiasis as a sequela after SARS-CoV-2 infection: A case report.

Gabriela Araújo da Costa1, Rani Iani Costa Gonçalo2, Marcos Antônio Lima Dos Santos3, Lucas Celestino Guerzet Ayres4,5, Breno Ferreira Barbosa5, Cleverson Luciano Trento4, Wilton Mitsunari Takeshita4, Lucas Alves da Mota Santana4.   

Abstract

Entities:  

Year:  2022        PMID: 36249460      PMCID: PMC9539338          DOI: 10.1111/ors.12777

Source DB:  PubMed          Journal:  Oral Surg        ISSN: 1752-2471


× No keyword cloud information.
Dear Editor, A 27‐year‐old female presented on December 15, 2020, with vast symptomatology, including vomiting, cough, fever, headache, myalgia, sore throat, xerostomia, anosmia, hypogeusia and diarrhoea. The physical examination revealed 37.5°C body temperature and oxygen saturation (SpO2) of 98% on room air. She was monitored under home quarantine for 15 days, having their oxygen saturation daily measured, under antibiotic and corticosteroid therapy. Posteriorly, the RT‐PCR result confirmed the diagnosis of COVID‐19. Despite the improvement in the general clinical frame of the patient, xerostomia remains a persistent symptom. In March 2021, the patient attended our oral medicine service showing an asymptomatic and erythematous lesion on the lateral border of the tongue. Curiously, in an 8‐month follow‐up, it was observed a second lesion in the central region of the dorsum with clinical features similar to the previous alteration. Medical history revealed no abnormalities. Due to clinical findings and previous infection by SARS‐CoV‐2, the diagnostic hypothesis of erythematous candidiasis as a consequence of COVID‐19 was raised. As a conduct, it was oriented oral hygiene with the use of tongue cleaner and daily mouthwash with nystatin for 14 days. Despite all clinical and pharmacological interventions, candidiasis remained a persistent lesion, mainly as a consequence of reduced salivary flow induced (Figure 1). Currently, she is under periodic clinical follow‐up and using sialogogues to salivation stimulate.
FIGURE 1

Intraoral aspect of lesion observed in the tongue compatible with erythematous candidiasis. (A) ‐ initial aspect of the alteration with a marked presence of erythematous erosive areas in tongue dorsum and lateral border of erythematous aspect (red circles); (B) – Clinical presentation after 7 days of use of nystatin with reduction of depapillation areas (red circles); (C) – Expressive reduction of erosive areas after 14 days of use of nystatin; (D) and (E) – Current aspect of the lesion with 1 month and 2 months, respectively after last attendance. Note to the concentration of erythematous area only in dorsum tongue (red circles).

Intraoral aspect of lesion observed in the tongue compatible with erythematous candidiasis. (A) ‐ initial aspect of the alteration with a marked presence of erythematous erosive areas in tongue dorsum and lateral border of erythematous aspect (red circles); (B) – Clinical presentation after 7 days of use of nystatin with reduction of depapillation areas (red circles); (C) – Expressive reduction of erosive areas after 14 days of use of nystatin; (D) and (E) – Current aspect of the lesion with 1 month and 2 months, respectively after last attendance. Note to the concentration of erythematous area only in dorsum tongue (red circles). Since COVID‐19's initial outbreak, several reports of oral lesions have been described in the literature. In general, these manifestations are characterized by the presence of epithelium alterations such as macules, erosions, ulcers, vesicles and blisters, observed mainly in moderate cases of the disease. , Although most cases had occurred in phases before vaccination, immunized patients as well may be affected. More than 2 years after being declared a pandemic by the WHO, the pathogenicity mechanism of the new coronavirus has not been fully elucidated, however, an intrinsic relationship with ACE‐2 receptors has been established. Interestingly, oral tissues show a high concentration of this protein that justifies the presence of the pathogen in the saliva and subsequent transmission through droplets and aerosols. , In a pioneer study, Matuck et al. (2021) employing laboratory techniques and histopathological analysis of necropsy samples demonstrated that salivary is a potential reservoir for replication of SARS‐CoV‐2. Besides, the pathophysiology of COVID‐19 is characterized by the presence of severe vasculitis and thrombosis, largely mediated by an exacerbated inflammatory response defined as a “cytokine storm”. For reason this, the inflammatory process itself could lead to morphological and functional alterations in acinar cells, with consequent damage to the salivary gland parenchyma. Curiously, the number of Sjögren's syndrome cases and salivary disturbers in Brazil increased significantly compared to periods before the pandemic. Also, it is known that reduced salivary flow is considered an important risk factor for the development of opportunistic infections, including oral candidiasis. Thus, the irreversibility of the damage to the tissue of the salivary glands could justify the persistence of xerostomia, in some patients, even after infection, as observed in the present case. In concordance, Melo et al. (2022) have mentioned the occurrence of Sicca syndrome episodes in patients with post‐acute COVID‐19 syndrome. In their retrospective study, Favia et al. (2021) observed that of the total of 123 cases of patients diagnosed with COVID‐19 and presenting oral lesions, 28 patients (22.7%) had candidiasis, most of them being erythematous. Moreover, SARS‐CoV‐2 can provoke an unbalance in the individual's resident microbiota in a process recognized as dysbiosis and, consequently, favouring the proliferation of pathogens that may influence the severity of the disease. Therefore, several cases of lesions observed in SARS‐CoV‐2 positive patients can be a result of this complex mechanism, with the virus can act as both primary and secondary agent in the development of the alterations. The occurrence of a persistent lesion in patients affected by novel coronavirus may represent a challenge to health services, beyond the impact on people's quality of life. In summary, for some individuals, a long follow‐up becomes necessary, mainly by damage to organic structures being unpredictable and those that occasionally were infected in the period before vaccination, whose inflammatory response has been more exacerbated.

AUTHOR CONTRIBUTIONS

All authors contributed equally to the manuscript.

FUNDING INFORMATION

No funding sources supported the preparation of this article.

CONFLICT OF INTEREST

None.

ETHICS STATEMENT

None required.
  12 in total

1.  Oral dysbiosis and its linkage with SARS-CoV-2 infection.

Authors:  Abhishek Gupta; Shivang Bhanushali; Avinash Sanap; Madhura Shekatkar; Avinash Kharat; Chandrashekhar Raut; Ramesh Bhonde; Yogesh Shouche; Supriya Kheur; Avinash Sharma
Journal:  Microbiol Res       Date:  2022-05-04       Impact factor: 5.070

Review 2.  COVID-19 infection: an overview on cytokine storm and related interventions.

Authors:  Raheleh Farahzadi; Tohid Ghasemnejad; Soheila Montazersaheb; Seyed Mahdi Hosseiniyan Khatibi; Mohammad Saeid Hejazi; Vahideh Tarhriz; Afsaneh Farjami; Faramarz Ghasemian Sorbeni
Journal:  Virol J       Date:  2022-05-26       Impact factor: 5.913

3.  Oral candidiasis of COVID-19 patients: Case report and review of evidence.

Authors:  Abanoub Riad; Esraa Gomaa; Barbora Hockova; Miloslav Klugar
Journal:  J Cosmet Dermatol       Date:  2021-03-21       Impact factor: 2.696

4.  Covid-19 Symptomatic Patients with Oral Lesions: Clinical and Histopathological Study on 123 Cases of the University Hospital Policlinic of Bari with a Purpose of a New Classification.

Authors:  Gianfranco Favia; Angela Tempesta; Giuseppe Barile; Nicola Brienza; Saverio Capodiferro; Maria Concetta Vestito; Lucilla Crudele; Vito Procacci; Giuseppe Ingravallo; Eugenio Maiorano; Luisa Limongelli
Journal:  J Clin Med       Date:  2021-02-13       Impact factor: 4.241

Review 5.  Morphological and tissue-based molecular characterization of oral lesions in patients with COVID-19: A living systematic review.

Authors:  Felipe Martins Silveira; André Luiz Rodrigues Mello; Laura da Silva Fonseca; Luíse Dos Santos Ferreira; Laura Borges Kirschnick; Manoela Domingues Martins; Lauren Frenzel Schuch; José Alcides Almeida de Arruda; Ciro Dantas Soares; Alexandre de Oliveira Sales; Ronell Bologna-Molina; Alan Roger Santos-Silva; Ana Carolina Uchoa Vasconcelos
Journal:  Arch Oral Biol       Date:  2022-02-12       Impact factor: 2.633

6.  ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium.

Authors:  Fucun Zhu; Yi Zhong; Huan Ji; Ran Ge; Lu Guo; Haiyang Song; Heming Wu; Pengfei Jiao; Sheng Li; Chenxing Wang; Hongming Du
Journal:  J Anat       Date:  2021-09-29       Impact factor: 2.921

7.  Sicca symptoms in post-acute COVID-19 syndrome.

Authors:  Thayanara Silva Melo; Renata Cristina Beltrão; Andréia de Fátima Trindade de Mendonça; Ângela Luzia Branco Pinto Duarte; Luiz Alcino Gueiros
Journal:  Oral Dis       Date:  2022-02-17       Impact factor: 4.068

8.  Oral mucosa lesions in confirmed and non-vaccinated cases for COVID-19: A systematic review.

Authors:  Lucas Alves da Mota Santana; Walbert de Andrade Vieira; Rani Iani Costa Gonçalo; Marcos Antônio Lima Dos Santos; Wilton Mitsunari Takeshita; Lucyene Miguita
Journal:  J Stomatol Oral Maxillofac Surg       Date:  2022-05-10       Impact factor: 2.480

9.  Oral and dermatologic lesions observed in mild COVID-19 patients infected after 3rd vaccine dose.

Authors:  Lucas Alves da Mota Santana; Gabriela Araújo da Costa; Rani Iani Costa Gonçalo; Wilton Mitsunari Takeshita; Lucyene Miguita
Journal:  Oral Dis       Date:  2022-05-01       Impact factor: 4.068

10.  Increase in the number of Sjögren's syndrome cases in Brazil in the COVID-19 Era.

Authors:  Hercílio Martelli Júnior; Luiz Alcino Gueiros; Edson Gomes de Lucena; Ricardo D Coletta
Journal:  Oral Dis       Date:  2021-05-27       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.